P/E ratio for Eterna Therapeutics (ERNA)

P/E ratio history for Eterna Therapeutics from 2021 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Baxter BAX	6.59	-21,417.51%	🇺🇸 USA
Geron GERN	-4.85	15,594.13%	🇺🇸 USA
Omeros Corporation OMER	13.2	-42,899.30%	🇺🇸 USA
Sanofi SNY	17.6	-56,862.50%	🇫🇷 France
Bio-Techne TECH	37.4	-121,074.06%	🇺🇸 USA
Genetic Technologies GENE	N/A	N/A	🇦🇺 Australia
Teva Pharmaceutical Industries TEVA	-7.54	24,283.93%	🇮🇱 Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.